Novartis | NOVN - Interest Expense On Debt

Stock Price
121.78
Daily Change
0.34 0.28%
Monthly
-4.40%
Yearly
23.72%
Q1 Forecast
118.31

Novartis reported $281M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alcon AG USD 54M 3M Dec/2025
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Autolus Therapeutics Ltd USD 10.52M 17.35M Sep/2025
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 85M 8.1M Dec/2025
Galapagos EUR 1.72M 940K Sep/2025
Genmab DKK 37M 28M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
J&J USD 18M 290M Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 121M 5M Dec/2025
Merck USD 412M 85M Dec/2025
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Orion EUR 600K 600K Sep/2025
Pfizer USD 711M 59M Dec/2025
Philips EUR 109M 31M Dec/2025
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
UCB EUR 78M 30M Jun/2025